

Table S2: Comparison of inhibitory activity between irreversible (Ibrutinib) and reversible (ARQ531) inhibitors

Inhibitors	Synonymous	WT/Mut	IC ₅₀	References
Ibrutinib	PCL-32765	BTK WT	0.5 nM	[1]
			0.72 nM	[2]
		BTK Cys481	9.03 nM	[3]
			4.6 nM	[1]
ARQ531	MK-1026	BTK WT	0.85 nM	[3]
		BTK Cys481	0.39 nM	[3]

1. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Louny, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, 107, (29), 13075-80.
2. Johnson, A. R.; Kohli, P. B.; Katewa, A.; Gogol, E.; Belmont, L. D.; Choy, R.; Penuel, E.; Burton, L.; Eigenbrot, C.; Yu, C.; Ortwine, D. F.; Bowman, K.; Franke, Y.; Tam, C.; Estevez, A.; Mortara, K.; Wu, J. S.; Li, H.; Lin, M.; Bergeron, P.; Crawford, J. J.; Young, W. B., Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. *ACS Chem. Biol.* **2016**, 11, (10), 2897-2907.
3. Sudharshan Eathiraj; Ronald E. Savage; Yi Yu; Brian Schwartz; Sean D. Reiff; Jennifer A. Woyach; Amy J. Johnson; Abbadessa, G., Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK. *Clinical Lymphoma Myeloma & Leukemia*. **2016**, 16.